EVIDENCE BASED PUBLIC HEALTH POLICY AND PRACTICE

Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA study

Jaume Marrugat, Isaac Subirana, Eva Comín, Carmen Cabezas, Joan Vila, Roberto Elosua, Byung-Ho Nam, Rafel Ramos, Joan Sala, Pascual Solanas, Ferran Cerdón, Joan Gené-Badia, Ralph B D'Agostino, for the VERIFICA (Validez de la Ecuación de Riesgo Individual de Framingham de Incidentes Coronarios Adaptada*) Investigators

J Epidemiol Community Health 2007;61:40–47. doi: 10.1136/jech.2005.038505

See end of article for authors' affiliations

Correspondence to: J Marrugat, Lípids and Cardiovascular Epidemiology Unit, Institut Municipal d'Investigació Mèdica (IMIM), Carrer Dr Aiguader, 88, 08003 Barcelona, Spain; jmarrugat@imim.es

Accepted 11 May 2006

Background: To assess the reliability and accuracy of the Framingham coronary heart disease (CHD) risk function adapted by the Registre Gironí del Cor (REGICOR) investigators in Spain.

Methods: A 5-year follow-up study was completed in 5732 participants aged 35–74 years. The adaptation consisted of using in the function the average population risk factor prevalence and the cumulative incidence observed in Spain instead of those from Framingham in a Cox proportional hazards model. Reliability and accuracy in estimating the observed cumulative incidence were tested with the area under the curve comparison and goodness-of-fit test, respectively.

Results: The Kaplan–Meier CHD cumulative incidence during the follow-up was 4.0% in men and 1.7% in women. The original Framingham function and the REGICOR adapted estimates were 10.4% and 4.8%, and 3.6% and 2.0%, respectively. The REGICOR-adapted function's estimate did not differ from the observed cumulative incidence (goodness of fit in men, $p=0.078$, in women, $p=0.256$), whereas all the original Framingham function estimates differed significantly ($p<0.001$). Reliabilities of the original Framingham function and of the best Cox model fit with the study data were similar in men (area under the receiver operator characteristic curve 0.68 and 0.69, respectively, $p=0.273$), whereas the best Cox model fitted better in women (0.73 and 0.81, respectively, $p<0.001$).

Conclusion: The Framingham function adapted to local population characteristics accurately and reliably predicted the 5-year CHD risk for patients aged 35–74 years, in contrast with the original function, which consistently overestimated the actual risk.

The acute myocardial infarction (AMI) mortality and incidence rates are unexpectedly low in France and Spain, considering the high consumption of saturated fatty acids and the high prevalence of cardiovascular risk factors, respectively.^{1–3} However, coronary heart disease (CHD) will continue to be among the leading causes of death in these countries.^{4–5} These facts demand the development of preventive strategies adapted to local cumulative incidence and risk factor prevalence characteristics. Individual risk stratification is essential for such strategies.⁶ Unfortunately, calculations based on the Framingham Heart Study risk functions overestimate the actual individual risk in Spanish patients, among others.^{7–14}

The Registre Gironí del Cor (REGICOR) investigators adapted the Framingham function to the Spanish population characteristics. The Framingham function was based on a Cox proportional hazards model to compare individual absolute risk with the average population risk of the corresponding sex. The adaptation consisted of estimating the average population risk with the risk factor prevalence and cumulative incidence observed in Spain.^{13–15} This method to adapt the Framingham function had been proved accurate for several ethnic groups,^{8–13} although the REGICOR adaptation had not been validated in Spain.

This study examines the accuracy and reliability of the original Framingham function and its REGICOR adaptation in predicting 5-year CHD cumulative incidence in a Spanish cohort aged 35–74 years recruited between 1995 and 1998. Separate analyses were done for men, women and patients with diabetes.

METHODS

The Validez de la Ecuación de Riesgo Individual de Framingham de Incidentes Coronarios Adaptada (Validity of the Adapted Framingham Individual Risk Equation for Coronary Incidents; VERIFICA) study consisted of a 5-year follow-up of a Spanish cohort aged 35–74 years, recruited between 1995 and 1998, initially free of symptoms of CHD and for whom complete baseline data on risk factors were available. Of the 5736 participants, 4430 were randomly selected from the clinical records of 67 Spanish primary care centres that volunteered to participate in the study. These centres covered the most populated areas of Spain (ie, Andalusia, Aragon, Basque Country, Balearic Islands, Catalonia, Extremadura, Galicia, Madrid and Navarre). A prospective population-representative cohort recruited in 1995 ($n=1306$, response rate 72% at the time of recruitment) was also included in the study³ (fig 1). The study was approved by the local ethics committee.

Assuming that the observed event rate would be 10% and the minimum difference to be detected from this figure to achieve statistical significance is 6% in the subgroup of highest risk (ie, $\geq 10\%$ at 5 years), the sample size provides a statistical power $>95\%$ in men and in patients with diabetes and $>80\%$ in women, for a 5% significance level.

Abbreviations: AMI, acute myocardial infarction; CHD, coronary heart disease; ECG, electrocardiogram; HDL, high-density lipoprotein; REGICOR, Registre Gironí del Cor; VERIFICA, Validez de la Ecuación de Riesgo Individual de Framingham de Incidentes Coronarios Adaptada (Validity of the Adapted Framingham Individual Risk Equation for Coronary Incidents)

Figure 1 Flowchart of participant inclusion in the combined cohorts. BP, blood pressure; CHD, coronary heart disease; HDL, high-density lipoprotein.

All established major cardiovascular risk factors were measured by standard methods.³⁻¹⁶ Participants were considered to be diabetic if they had been diagnosed with diabetes and were following a diabetic diet or taking drugs such as oral agents or insulin. Participants with a history of hypertension, under treatment for hypertension, or with systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg were considered hypertensive. Those who reported smoking >1 cigarette/day in the preceding year were considered smokers. All necessary baseline lipid and blood pressure measurements were collected to estimate the risk of each participant. In the primary care centres, the last recorded value was used unless more than one value existed in clinical records for the year before the date of recruitment; in that case, the average systolic and diastolic blood pressure and the average total and high-density lipoprotein (HDL) cholesterol from these visits were recorded.

In the population cohort, a 5-year follow-up with a personal contact was organised to obtain an electrocardiogram (ECG) and administer a structured questionnaire to determine whether coronary events had occurred in the interim. All hospital and general practitioners' clinical records for all hospitalised or deceased participants were examined to ascertain the discharge diagnosis or cause of death. In fatal cases, relatives were interviewed when deemed necessary to clarify the cause of death.

In the retrospective primary-care cohort, medical records and re-examination as necessary were used to identify patients who experienced coronary events during the follow-up period.

A patient was censored at the time of the first eligible event or at the time the final contact was established; in four cases this was <1 year after inclusion.

Eligible outcomes during follow-up

The CHD events considered include: (1) non-fatal AMI, determined when hospital clinical records indicated a characteristic ECG, enzyme or troponin increase (not explained

by other conditions), with suggestive symptoms, and the patient survived at least 28 days after symptom onset; (2) fatal AMI, when all AMI criteria were met and the patient died within 28 days of symptom onset, a diagnostic necropsy existed or sudden death occurred with suggestive symptoms that could not be explained by other diseases (when a patient with a non-fatal AMI died >28 days after onset of symptoms, two events were recorded); (3) angina pectoris, when at least a positive ischaemia test or coronary angiography was reported or characteristic ECG changes occurred during chest pain; (4) unrecognised AMI in the population cohort, when the follow-up ECG showed Q waves or ischaemia signs that were absent in the initial ECG examination and were confirmed by echocardiography and cardiac scintigraphy showing signs of a myocardial scar. All ECG were blindly interpreted and compared with the baseline ECGs by the same senior cardiologist.

Risk functions

All estimates were for 5-year risk. The risk functions used in this study include the Framingham function¹⁷ and the REGICOR adaptation to the risk factor prevalence and event characteristics of the population in Spain.¹⁵

Statistical analysis

Clinical records from a random sample of 15% of all participants selected in the primary care setting were re-examined by trained external personnel for quality control purposes. κ and intra-class correlation coefficient agreement statistics were used to determine the accuracy of data collected by local investigators.

The cohort was divided into four groups of probability according to the original Framingham function, using 5-year risk cut-points at 5%, 7.5% and 10%; this represented a good approximation to the 10%, 15% and 20% risk cut-points used in clinical practice for 10-year risk.

Table 1 Baseline characteristics and events by sex in the Spanish cohort of the Validez de la Ecuación de Riesgo Individual de Framingham de Incidentes Coronarios Adaptada (or Validity of the Adapted Framingham Individual Risk Equation for Coronary Incidents) study

	All n=5732, n (%)	Women n=3285, n (%)	Men n=2447, n (%)
Age (years)*	56.3 (10.5)	56.8 (10.4)	55.7 (10.6)
Diagnosed diabetes	941 (16.4)	481 (14.6)	460 (18.8)
SB (mm Hg)*	135.1 (18.4)	135.2 (18.8)	135.0 (17.8)
DBP (mm Hg)*	81.4 (10.6)	80.9 (10.8)	81.9 (10.3)
Blood pressure (categories; mm Hg)			
Optimal SBP<120 and DBP<80	754 (13.2)	467 (14.2)	287 (11.7%)
Normal SBP 120–129 or DBP 80–84	999 (17.4)	550 (16.7)	449 (18.3)
Normal-high SBP 130–139 or DBP 85–89	1273 (22.2)	678 (20.6)	595 (24.3)
Grade I SBP 140–159 or DBP 90–99	1925 (33.6)	1139 (34.7)	786 (32.1)
Grades II–III SBP≥160 or DBP≥100	781 (13.6)	451 (13.7)	330 (13.5)
Previous diagnosis of hypertension	2568 (44.8)	1549 (47.2)	1019 (41.7)
Pharmacological treatment of hypertension	1771 (30.9)	1107 (33.8)	664 (27.3)
Total cholesterol (mg/dl)*	231.8 (41.5)	234.1 (42.1)	228.8 (40.5)
Total cholesterol (mg/dl; categories)			
<160	215 (3.8)	107 (3.3)	108 (4.4)
160–199	1052 (18.4)	573 (17.4)	479 (19.6)
200–239	2060 (35.9)	1152 (35.1)	908 (37.1)
240–279	1727 (30.1%)	1013 (30.8%)	714 (29.2%)
≥280	678 (11.8)	440 (13.4)	238 (9.7)
HDL cholesterol (mg/dl)*	53.7 (14.7)	57.6 (14.2)	48.5 (13.6)
HDL cholesterol (mg/dl; categories)			
<35	368 (6.4)	94 (2.9)	274 (11.2)
35–44	1249 (21.8)	450 (13.7)	799 (32.7)
45–49	896 (15.6)	505 (15.4)	391 (16)
50–59	1466 (25.6)	913 (27.8)	553 (22.6)
≥60	1753 (30.6)	1323 (40.3)	430 (17.6)
Pharmacological treatment of cholesterol	661 (11.5)	398 (12.1)	263 (10.6)
Active smoker	1418 (24.7)	347 (10.6)	1071 (43.8)
History			
Cerebrovascular disease	98 (1.7)	44 (1.3)	54 (2.2)
Congestive heart failure	67 (1.2)	39 (1.2)	28 (1.1)
Peripheral artery disease	63 (1.1)	18 (0.5)	45 (1.8)
Valve disease	89 (1.6)	45 (1.4)	44 (1.8)
Original Framingham function 5-year risk*	7.2 (6.3)	4.8 (3.7)	10.4 (7.6)
Adjusted REGICOR function 5-year risk*	2.7 (2.3)	2.0 (1.6)	3.6 (2.8)
Kaplan–Meier observed 5-year event rate (%)	3.2	1.7	4.0
Numbers of eligible outcomes			
Fatal myocardial infarction	16	9	7
Non-fatal myocardial infarction (with symptoms)	44	9	35
Unrecognised myocardial infarction†	3	2	1
Angina	117	48	69
Any of the above	180	68	112

DBP, diastolic blood pressure; HDL, high-density lipoprotein; REGICOR, Registre Gironí del Cor; SBP, systolic blood pressure.

*Mean (SD).

†New Q waves observed in follow-up ECG, obtained only in the population cohort.

The Framingham function adaptation consists essentially in replacing the Framingham cumulative incidence and risk factor prevalence by those of the country in which it is intended to be applied (ie, Spain in our case). This method has been extensively described elsewhere.^{7 8 15}

Accuracy and reliability of the classification provided by the original and REGICOR-adapted Framingham functions were assessed separately by sex as follows:

1. The coefficients estimated by the Cox model that best fitted the cohort data (best Cox) were compared with those of the original Framingham function by a z score test.^{8 18} For statistical power reasons, the model was fitted with total-cholesterol and HDL-cholesterol as continuous variables.
2. A calibration test, by sex, assessed the accuracy of the original Framingham and REGICOR-adapted functions by comparing

their estimated risk equations with the observed event rate in the four risk groups established by the original Framingham function. The D'Agostino–Nam version of the Hosmer and Lemeshow goodness-of-fit test was used to calculate a χ^2 value.^{8 18} χ^2 values <6 were considered to indicate a substantial fit for four groups, regardless of the p value.¹⁸

3. The discrimination capacities of the original and adapted Framingham functions were analysed by comparing the area under the curve obtained by the receiver operator characteristics of the original function and that obtained by the best Cox model fit of CHD event fitted to the cohort data. It is important to note that the adaptation procedure does not affect discrimination.

Kaplan–Meier survival estimates were used to calculate 5-year observed cumulative incidence. The analyses were done

Figure 2 Distribution of participants, by sex, in four groups of coronary heart disease risk according to the 5-year Framingham function, showing the observed event rate and the rate expected by the REGICOR-adapted and original Framingham functions, together with the goodness-of-fit χ^2 statistics and significance levels.

with S-Plus 2000 (Insightful Corporation, Seattle, Washington, USA) and SAS V.8.2.

RESULTS

Table 1 presents the risk factors, 5-year risk estimates and baseline characteristics of the 5732 participants, with complete follow-up by sex.

Quality control

The κ statistics comparing the categorical data collected by the study investigators and those extracted from clinical records by trained independent investigators were >0.75 for risk factors and demographic data, and >0.84 for type of event during follow-up. Intraclass correlation coefficients (age, total and HDL cholesterol, systolic and diastolic blood pressure) were >0.90 in all instances, indicating good to excellent agreement.

Follow-up

The observed number of patients with at least one CHD event was 180 (table 1); 41% of 5-year overall CHD and 69.8% of fatal CHD events occurred after age 65 years. In addition, 24 fatal non-CHD cardiovascular events and 107 non-cardiovascular deaths were observed during follow-up. Only four patients were lost to follow-up.

The original Framingham function overestimated the observed event rate in women and men by a factor of 2.8 and 2.6, respectively. The REGICOR-adapted function improved substantially the goodness of fit for both sexes: the distribution of observed events did not differ from that predicted by the adapted function (fig 2).

We fitted a proportional hazards Cox model with the cohort data to estimate the β coefficients for each risk factor level. None of the coefficients significantly differed from the original

Figure 3 Area under the receiver operating curves for the predicted risk according to the original function and the best Cox model fit with the study cohort, by sex.

Framingham function in men and only that of smoking differed in women (table 2).

The area under the receiver operator characteristic curve obtained with the best-fitting Cox function was similar to that of the original Framingham function in men, indicating a similar discrimination capacity. By contrast, the best Cox model fit provided a higher area under the curve than the original function in women, suggesting that the coefficients estimated with local data significantly improved the identification of women who developed an event during follow-up (fig 3).

In men and women with diabetes ($n = 941$), the Kaplan-Meier observed overall 5-year CHD event rate was 4.9%. The original Framingham function significantly overestimated the event rate by a factor >2.6 ; the prediction of the REGICOR-adapted function did not differ from the observed rate (fig 4).

DISCUSSION

The study findings show that the accuracy of the CHD risk estimated by the REGICOR-adapted function is better than that of the original Framingham function in Spanish men, women and patients with diabetes. The REGICOR adaptation has proved to reliably provide accurate CHD risk estimates for ages 35-74 years in Spain. The adaptation method is a valid instrument for CHD risk assessment in countries with cardiovascular risk factor and event rate characteristics different from those of the Framingham population.

An overestimation of risk by the Framingham function has been shown to exist not only in the Spanish population⁷ but

Table 2 Estimates of the coefficients for each variable included in the Framingham original function and in the best Cox model adjusted for treatments for hypertension and lipid lowering, by sex

	Men					Women				
	Framingham original		REGICOR Best Cox		z score p Value	Framingham original		REGICOR Best Cox		z-score
	Coef	SE	Coef	SE		Coef	SE	Coef	SE	
Age	0.049	0.005	0.043	0.012	0.631	0.338	0.074	0.291	0.222	0.84
Age >2 years	—	—	—	—	—	−0.003	0.001	−0.002	0.002	0.56
Total cholesterol (1 mg)	0.007	0.001	0.002	0.003	0.067	0.005	0.002	−0.001	0.004	0.119
HDL cholesterol (1 mg)	−0.027	0.005	−0.02	0.009	0.485	−0.027	0.005	−0.048	0.012	0.093
Blood pressure classification										
Optimal SBP<120 and DBP<80 mm Hg	−0.009	0.194	−0.589	0.522	0.298	−0.52	0.256	−0.014	0.704	0.499
Normal SBP 120–129 or DBP 80–84 mm Hg	—	—	—	—	—	—	—	—	—	—
Normal-high SBP 130–139 or DBP 85–89 mm Hg	0.275	0.171	−0.147	0.358	0.288	−0.047	0.231	−0.043	0.495	0.992
HT Grade I SBP 140–159 or DBP 90–99 mm Hg	0.524	0.159	0.339	0.321	0.604	0.269	0.205	−0.046	0.444	0.52
HT Grades II–III SBP≥160 or DBP≥100 mm Hg	0.631	0.173	0.126	0.408	0.254	0.485	0.218	0.162	0.499	0.553
Diagnosed diabetes	0.417	0.177	0.017	0.259	0.201	0.617	0.212	0.798	0.3	0.622
Current smoker	0.53	0.104	0.564	0.215	0.886	0.235	0.142	1.382	0.44	0.017

Coef, coefficient in the proportional hazards regression model; DBP, diastolic blood pressure; HDL, high-density lipoprotein; HT, hypertension; REGICOR, Registre Gironí del Cor; SBP, systolic blood pressure.

also in northern and western European countries.^{9–12} For example, an overestimation of about 60% was observed in the UK¹⁴; however, this is far from the >260% overestimation observed in Spain.⁷ The greater magnitude of the overestimation in Spain may be related to the fact that the relative risk of CHD for higher values of total cholesterol and blood pressure as compared with lowest values is similar in all countries, but the absolute risk strongly depends on the country where data are gathered.^{19–20} If we are to adequately predict CHD risk in areas where the AMI incidence rate is, comparatively, very low, we need to urgently adapt the Framingham function to the population characteristics of those countries, to prevent over-treatment, particularly with lipid-lowering drugs, stemming from risk overestimation.

The accuracy of risk estimates is a key to determine the best primary prevention strategies, and has important practical implications. For example, even in regions of high CHD incidence, the low cost effectiveness of statin use in primary prevention makes it difficult for public health services to assume this expense.^{21–23} Primary prevention in Spain, a country of low CHD incidence (eg, half to one-third the incidence in

UK),¹ is even less cost effective. The effectiveness and safety of long-term primary prevention with statins remains uncertain, at least in patients with low-to-moderate coronary risk.^{24–25}

Characteristics and limitations of the study

Hypertension and lipid-lowering drugs may be independent factors that modulate the coefficient estimates for risk factors. In our study, none of these treatments was independently associated with event occurrence in either sex (data not shown). However, the best Cox model fit was adjusted for both.

The fact that the coefficient for smoking was significantly higher for women in the best Cox model fit than for those in the original function suggests that smoking may be more relevant to CHD development for women in Spain, where the incidence rate for smoking is much lower than that in Framingham. It should be noted, of course, that the prevalence of smoking in younger women in Spain was much lower than in Framingham 30 years ago, but has been increasing in recent years. However, the cumulative incidence observed in the last 15 years in Spain still corresponds to the effects of low exposure to smoking 30 years ago. Therefore, applying the Framingham β for smoking in Spain may still lead to an overestimation of the effect, given the lag in women's exposure to smoking.

We used the population-based sample to test whether any difference existed in the results as compared with the overall cohort. Beyond the sample size restrictions, no substantial differences were found (results not shown) in this subgroup analysis.

The diabetic subgroup showed a higher 5-year event rate (5.3%) and higher risk (2.5%) than the rest of the general population in our study. The latest publications have found the event risk in CHD patients without diabetes to be 1.9 times higher than that in CHD-free patients with diabetes.²⁶ A controversy exists as to whether the increased cardiovascular risk of patients with diabetes should lead to secondary prevention intervention in these patients.^{27–29} These findings support the principle of applying caution in this context: patients with diabetes should be more carefully followed and may need more intensive regimens of treatment with drugs, but it is difficult to accept that they must be assigned the same level of risk as patients offered secondary prevention. We could not

Figure 4 Distribution of patients with diabetes in four groups of coronary heart disease risk according to the 5-year Framingham function, showing the observed event rate and the rate expected by the REGICOR-adapted and original Framingham functions.

What is already known

- Individual risk stratification is essential for primary preventive strategies to be properly set up.
- The risk calculations based on the Framingham Heart Study risk functions overestimate the actual individual risk in many countries.
- Adapting the cardiovascular risk functions to local risk and risk factor prevalence characteristics has been recommended to obtain accurate local estimates.

What this study adds

- The accuracy of the coronary heart disease (CHD) risk estimated by the Registre Gironí del Cor (REGICOR)-adapted function is better than that of the original Framingham function in Spanish men, women and patients with diabetes.
- To date, the REGICOR adaptation is the only one that has proved to reliably provide accurate CHD risk estimates for people aged 35–74 years in Spain.

Policy implications

- Given the fact that the REGICOR adaptation of the Framingham cardiovascular risk function is the only study to have shown accuracy and reliability in a Spanish population aged 35–74 years, it should be adopted as the standard for this population. Other cardiovascular risk functions should be validated in the target population before they can be safely used in this country.
- Accurate cardiovascular risk estimates will contribute to more precise determination of the subset of population in which best primary prevention activities should be more intensively pursued and, in consequence, to improved cost effectiveness of treatment with drugs, particularly with lipid-lowering drugs.

undertake appropriate subgroup analysis of patients with diabetes by sex due to limited statistical power.

The fatal and symptomatic non-fatal AMI annual incidence rate observed in our study is higher than that observed in Spain in the population aged 35–74 years (122 and 81 per 100 000 women, and 420 and 314 per 100 000 men, respectively), which is consistent with the predominantly primary care origin of the studied cohort.³⁰

In summary, the original Framingham function applied to the Spanish population significantly overestimated the 5-year observed CHD rate. However, the adapted function reliably and accurately predicted the observed 5-year CHD cumulative incidence. Adaptation of the Framingham function is a valid alternative to the creation of new functions derived from local cohorts.

ACKNOWLEDGEMENTS

We appreciate the English language editing done by Elaine Lilly, PhD, of Writer's First Aid.

Authors' affiliations

J Marrugat, I Subirana, J Vila, R Elosua, R Ramos, Unitat de Lípids i Epidemiologia Cardiovascular, Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain

E Comín, Institut Català de la Salut, Barcelona, Spain

C Cabezas, Fundació Gol i Gurina and Institut Català de la Salut, Barcelona, Spain

J Marrugat, P Solanas, F Cerdón, Universitat Autònoma de Barcelona, Barcelona, Spain

J Sala, Servei de Cardiologia i Unitat Coronària, Hospital de Girona Josep Trueta, Girona, Spain

P Solanas, F Cerdón, Unitat Docent de Medicina de Família de Girona, Institut Català de la Salut, Barcelona, Spain

J Gené-Badia, Consorci Atenció Primària de l'Eixample, Universitat de Barcelona, Barcelona, Spain

B-H Nam, R B D'Agostino, Framingham Heart Study and Boston University, Boston, Massachusetts, USA

Funding: This study was funded in part by the Institut Municipal d'Investigació Mèdica (IMIM), Institut Català de la Salut, Fundació Gol i Gurina' and by an educational grant from the Esteve Group, all in Barcelona, Spain. The study was also partially funded by the following Spanish Fondo de Investigación Sanitaria research networks: RECAVA (grant FIS C03/01), RCESP (grant FIS C03/09), REDIAPP-Catalunya (grant FIS G03/170) and HERACLES (grant FIS G03/045).

Competing interests: None declared.

Members of the scientific committee: Jaume Marrugat (PI), Carles Brotons, Carmen Cabezas, Joan Josep Cabré, Arantxa Catalán, Ramon Ciurana, Eva Comín, Ferran Cerdón, Joan Gené-Badia, Rafael Masía, Ramon Morera, Clara Pujol, Rafel Ramos, Joan Sala, Pascual Solanas, Maria-Concepció Violan.

A full roster of the VERIFICA Investigators is provided in the appendix and at www.regicor.org/verifica_inv.

REFERENCES

- 1 Pérez G, Pena A, Sala J, *et al.* Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in Gerona, Spain, 1990–1992. *Int J Epidemiol* 1998;**27**:599–604.
- 2 Artaud-Wild SM, Connor SL, Sexton G, *et al.* Differences in coronary mortality can be explained by differences in cholesterol and saturated fat intakes in 40 countries but not in France and Finland. *Circulation* 1993;**88**:2271–9.
- 3 Masía R, Pena A, Marrugat J, *et al.* High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. *J Epidemiol Comm Health* 1998;**52**:707–15.
- 4 Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. *Lancet* 1997;**3**:1269–76.
- 5 Marrugat J, Elosua R, Martí H. Epidemiología de la cardiopatía isquémica en España: estimación del número de casos y de las tendencias entre 1997 v 2005. *Rev Esp Cardiol* 2002;**55**:337–46.
- 6 Kannel WB, D'Agostino RB, Sullivan L, *et al.* Concept and usefulness of cardiovascular risk profiles. *Am Heart J* 2004;**148**:16–26.
- 7 Marrugat J, D'Agostino R, Sullivan L, *et al.* An adaptation of the Framingham coronary heart disease risk functions to European Mediterranean areas. *J Epidemiol Community Health* 2003;**57**:634–8.
- 8 D'Agostino RB, Grundy S, Sullivan LM, *et al.* Validation of the Framingham Coronary Heart Disease Prediction Scores. *JAMA* 2001;**286**:180–8.
- 9 Hense HW, Schulte H, Lowel H, *et al.* Framingham risk function overestimates risk of coronary heart disease in men and women from Germany: results from the MONICA Augsburg and the PROCAM cohorts. *Eur Heart J* 2003;**24**:937–45.
- 10 Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart risk function from an Italian population study. *Eur Heart J* 2000;**21**:365–70.
- 11 Thomsen TF, McGee D, Davidsen M, *et al.* A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. *Int J Epidemiol* 2002;**31**:817–22.
- 12 Menotti A, Lanti M, Puddu PE, *et al.* Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. *Heart* 2000;**84**:238–44.
- 13 Liu J, Hong Y, D'Agostino RB, *et al.* Predictive value for the Chinese population of the Framingham CHD Risk Assessment Tool compared with the Chinese Multi-provincial Cohort Study. *JAMA* 2004;**291**:2591–9.
- 14 Brindle P, Emberson J, Lampe F, *et al.* Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. *BMJ* 2003;**327**:1267–73.
- 15 Marrugat J, Solanas P, D'Agostino R, *et al.* Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. *Rev Esp Cardiol* 2003;**56**:253–61.
- 16 De Backer G, Ambrosini E, Borch-Johnsen K, *et al.* European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Eur Heart J* 2003;**24**:1601–10.
- 17 Wilson PWF, D'Agostino RB, Levy D, *et al.* Prediction of coronary heart disease using risk factor categories. *Circulation* 1998;**97**:1837–47.

- 18 **D'Agostino RB Sr**, Nam BH. Evaluation of the performance of survival analysis models: discrimination and calibration measures. In: Balakrishnan N, Rao C, eds. *Advances in survival analysis: handbook of statistics*. Vol 23. Amsterdam: Elsevier, 2004:1-25.
- 19 **Verschuren WM**, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the Seven Countries Study. *JAMA* 1995;**274**:131-6.
- 20 **Van den Hoogen PC**, Feskens EJ, Nagelkerke NJ, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. *N Engl J Med* 2000;**342**:1-8.
- 21 **Pignone M**, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. *BMJ* 2000;**321**:1-5.
- 22 **Raithatha N**, Smith RD. Paying for statins. *BMJ* 2004;**328**:400-2.
- 23 **Ramos R**, Solanas P, Córdón F, et al. Comparación de la función de Framingham original y la calibrada del REGICOR en la predicción del riesgo coronario poblacional. *Med Clin (Barc)* 2003;**121**:521-6.
- 24 **Jackson PR**, Wallis EJ, Haq IU, et al. Statins for primary prevention: at what coronary risk is safety assured? *Br J Clin Pharmacol* 2001;**52**:439-46.
- 25 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001;**285**:2486-97.
- 26 **Lee CD**, Folsom A, Pankow JS, et al. Cardiovascular events in diabetic and non-diabetic adults with or without history of myocardial infarction. *Circulation* 2004;**109**:855-60.
- 27 **Haffner SM**, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998;**339**:229-34.
- 28 **Evans JMM**, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. *BMJ* 2002;**324**:1-5.
- 29 **Lee C**, Folsom A, Pankow J, et al. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. *Circulation* 2004;**109**:855-60.
- 30 **Marrugat J**, Elosua R, Aldasoro E, et al. Regional variability in population acute myocardial infarction cumulative incidence and mortality rates in Spain 1997 and 1998. *Eur J Epidemiol* 2004;**19**:831-9.

APPENDIX

VERIFICA investigators

Centro de Salud (CS) Sant Pere, Reus, Joan Josep Cabré Vila, Francisco Martín Luján, Bernardo Costa Pinel, Josep Lluís Piñol Moreso, Josep Basora Gallisà, Àngel Donado-Mazarrón Romero, Jordi Bladé Creixenti, Rosa Solà Alberich; **CS Carranque, Málaga**, José Carlos Bravo; **CS Son Ferriol, Palma de Mallorca**, Tomàs Rodríguez Ruiz, Montserrat de la Torre Vidal, Catalina Mateu Sabater, Gorka Karla Iriarte Posse, Cristina Soriano Iglesias, Antonio Bernad Ceresuela; **CS Sàrdoma, Vigo**, Fernando Lago Deibe, Jacinto Mosquera Nogueira, José Ramón Moliner De la Puente, M^q Concepción Cruces Artero, Manuel Domínguez Sardiña, Juan Novoa Rodríguez, Luciano Casariego Barro, Joan Cristobal Torras; **EAP de Can Vidalet, Esplugues**, Isabel Porta Rey, Inés Monte Collado, Teresa Cabases Latorre, M^q Rosario Mateo Gambarte, Xavier Rodríguez Pascual, Rosa Batlle Granel, M^q Jesús Ceraín Herrero, M^q Teresa Julià Nicolàs; **CS Santa Clara, Girona**, Cristina Serra Ferrer, Silvia García Parajua, Concepció Bou Mias, Mercè Salvans Sagué, Montse Ribas Martín, Aurora Massaguer Fuster, M^q Carmen Asensio Aznar; **CS Guayaba, Madrid**, Francisco Gómez Martín, José Antonio Granados Garrido, Carmen Hernández Manzano, Isabel Gutiérrez Sánchez, Javier Martínez Suberviola, Sonia Sánchez Yubero, Elena Navarro Matías, Ana Pastor Rodríguez Moñino; **CS La Riera, Mataró**, Josep Lluís Anglada Barceló, Eugeni Fau Montllor, Elisa Sanz Moragas, Jordi Salabarnada Torras, Susana Morales Lozano, Carme Forcada Vega; **CS Iturrama, Pamplona**, María del Mar Hernández Espinosa, Maite Gaztelu Contín, Julián Carlos Amézqueta Goñi, Maite Salinas Vidondo, Ramón Villanueva Moreno; **CS San José Norte, Zaragoza**, Alejandro Marín Ibáñez; **CS Abrantes, Madrid**, Begoña Brusint Olivares, Elena Rojo Subiñas; Antonino Román Martínez, Javier Garijo Cobo, María Angeles De la Fuente Martínez, José Manuel Pérez Rodríguez-Amezcu; **CS Novoa**

Santos, Ourense, Alberto J del Alamo Alonso, Manuel González Rodríguez, Antonio González Alvarez; **CS de Salt, Salt**, Esteve Avellana Revuelta, Rafel, Ramos Blanes; **CS Pontones, Madrid**, Pilar Martín Rodríguez, Pilar Llorente Domingo, Carmen Romero Fortunez, María del Pilar Nieto Sánchez, María Jesús Fidalgo Baz, María Isabel Gámez Cabero, Margarita Gonzalez Polo; **CS Dr. Pujol i Capsada, Prat de Llobregat**, Esther López Gonzalo, Maribel Matilla Mort, Ana M^q Cuenca Olivas, Oscar Mazeres Ferrer, Eva Comín Bertran; **CS Perales del Río, Getafe**, María de las Mercedes Rojo Tardón, Cesar Minue Lorenzo, María Angeles Usero Martín; **CS Inca, Mallorca**, Luis Escriche, Mercedes Jalon Monzon, Basilio García Sanchez; **CS Almendrales, Madrid**, María José Ramírez Vallejo, Aurora García Lerin, Esther Picazo Gómez, Concepción Rodríguez Martín, Paloma Cauto Aragonés, Nuria Fernández Gutiérrez, Enrique Pereda Arregui; **CS Emili Darder, Palma de Mallorca**, Escarlata Angullo Martínez, Amador Ruiz Torrejón, Belén Gómez Queipo, Catalina Llabrés Campins; **CS La Paz, Badajoz**, Francisco Buitrago Ramírez, Lourdes Cañón Barroso; **CS Embajadores, Madrid**, María del Pilar Moro Torija, Francisco Javier San Andrés Rebollo, Victoria Heras Hernández, Juan Carlos López Andrino; **CS Son Pisà, Palma de Mallorca**, Miguel Góngora Andrade, Eugenia Carandell Jäger; **CS Verdúm, Barcelona**, Xavier Clar Guevara, Natividad Fernández Padilla, Silvia Güell Parnau; **CS Rosales, Madrid**, Elena López Parra, Francisco Javier Zufía García, Natividad Puche López; **CS Sant Just Desvern, Sant Just Desvern**, Purificación Robles Raya, Marina Payá Marco, Jesús Muniesa Minguillon, Xavier Serra Gabriel; **CS Delicias, Málaga**, Fernando López Verde, Jesús Díaz Jiménez; **CS Sant Miquel, Granollers**, Josep Espinasa Rifà; **CS de Sta Margarida de Montbui, Sta Margarida de Montbui**, Josep Alins i Presas; **CS La Mina, Sant Adrià de Besòs**, Carme Espel Masferrer, Silvia Calvet Junoy, Mariano de la Figuera Von Wichmann, Manuel Mata Cases, Ernest Vinyoles Bargalló, Enriqueta Pujol; **CS de La Bisbal, La Bisbal**, Jordi March Nogué, Helena Badia Capdevila; **CS de Tafalla, Tafalla**, María José Ariz Arnedo, Javier Díez Espino; **CS Catalina Cargol, Palamós**, Ignacio Pascual Cereceda, Xavier Casanovas Rigall, Jordi Coderch; **CS General Ricardos (Opañel II), Madrid**, César Jurado Valenzuela; **CS Potes, Madrid**, Rosario Serrano Martín, Javier Castellanos Maroto; **CS Lluís Millet, Esplugues de Llobregat**, Carme Turró Xiqué, Pere Barreto Ramón, Sandra Curto Sancho, María Llagostera; **CS de Marratxí, Marratxí**, Santiago Mairata Bosch, Manuel Franco; **CS de Desierto, Baracaldo**, Fernando Uribe Oyarbide; **CS General Ricardos, Madrid**, Asunción Prieto Orzanco, Raquel Mateo Fernández; **CS Montivili, Girona**, Pascual Solanas Saura, Carlos Cerezo Goyeneche, Ferran Cordon Granados; **CS San Martín, Vitoria**, Rosa Esquisábel Martínez; **CS de Pineda de Mar, Pineda de Mar**, Mercè Pérez Vera, Mercè Pol Pons, Esperança Almerich Latorre; **CS de Montornés del Vallés, Montornés del Vallés**, Miguel Angel Muñoz Perez, Eduardo Carrión Sánchez; **CS Villaba, Navarra**, Juan Carlos Cenoz Osinaga; **CS Borges Blanques, Borges Blanques**, Innocencia Bobadilla Machin; **CS Les Corts-Hèlios, Barcelona**, Ana Benavides Ruiz, Joan Mitjavila López, Antoni Sisó Almirall; **CS Arquitecto Bennisar, Palma de Mallorca**, Antonio Joan Jover Palmes, Carolina Tomàs Morin, Antonio Ballester Camps; **CS Balàfia-Pardinyes-Secà de Sant Pere, Lleida**, Plácido Santafé Soler, Ramón Sánchez Pellicer; **CS Camps Blancs, Sant Boi de Llobregat**, Alicia Val Jimenez; **CS de Les Preses, Les Preses**, Antoni Agustí Martí; **CS Dr Josep Alzina i Bofill, Palafrugell**, Concepció de Ribot Mundet; **CS de Tordera, Tordera**, Rosa Francisco Soms, Luis Villanueva Segarra; **CS Chantrea, Pamplona**, Carmen Fuertes Goñi; **CS**

Ermitagaña, Pamplona, Cristina Ibarrola Guillén; **CS Los Angeles, Madrid**, Miguel Ángel Delgado Nicolas, Sílvia Ayala Luna; **CS de Alza-Roteta, San Sebastian**, Carmen Olasagasti Caballero, Rafael Rotaache del Campo, Celestino Gómez Calatrava; **CS de Pasai Antxo, Pasai Antxo**, Eulali Mariñelarena Mañeru; **CS San Andrés-Torcal, Málaga**, Juan José Bedoya Belmonte; **EAP San Fermín, Madrid**, Cristina De Alba Romero, Alfonso Corrochano Pérez; **CS Sant Ildefons, Cornellà**, Marta Valls Esteve; **CS Manacor, Palma de Mallorca**, María Isabel Borràs Bosch; **CS de Sta Margarida de Montbui, Sta Margarida de Montbui**,

Josep Maria Sánchez Colom; **CS Cuevas de Almanzora, Cuevas de Almanzora**, Juan Pablo Sánchez Andrada, Ana Iranzo Luna, Maria Dolores Acosta González, Carlos Fernández Oropesa; **CS de Vilanova del Vallès, Vilanova del Vallès**, Francesca Zapater Torras; **CS Párroco Julio Morate, Madrid**, Fernando Romero Arroyo, Elena Aguilo Pastrana; **Ambulatorio de Tolosa, Tolosa**, Javier Hernando Aizpurua, Ina Idarreta Mendiola; **CS Azpilagaña. Navarra, Pamplona**, Manuel Serrano Martínez; **CS d'Arenys de Mar, Arenys de Mar**, Martí Fradera Subirana; **CS Florida, L'Hospitalet de Llobregat**, Juan José Rodríguez Cristobal.

Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. *Clinical Evidence* needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

Areas for which we are currently seeking contributors:

- Pregnancy and childbirth
- Endocrine disorders
- Palliative care
- Tropical diseases

We are also looking for contributors for existing topics. For full details on what these topics are please visit www.clinicalevidence.com/ceweb/contribute/index.jsp

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:

- Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
- Writing the text to a highly structured template (about 1500-3000 words), using evidence from the final studies chosen, within 8-10 weeks of receiving the literature search.
- Working with *Clinical Evidence* editors to ensure that the final text meets epidemiological and style standards.
- Updating the text every 12 months using any new, sound evidence that becomes available. The *Clinical Evidence* in-house team will conduct the searches for contributors; your task is simply to filter out high quality studies and incorporate them in the existing text.

If you would like to become a contributor for *Clinical Evidence* or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to CECommissioning@bmjgroup.com.

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Topics are usually 1500-3000 words in length and we would ask you to review between 2-5 topics per year. The peer review process takes place throughout the year, and out turnaround time for each review is ideally 10-14 days.

If you are interested in becoming a peer reviewer for *Clinical Evidence*, please complete the peer review questionnaire at www.clinicalevidence.com/ceweb/contribute/peerreviewer.jsp